Brolucizumab

Therapeutic indications

Brolucizumab is indicated for:

Neovascular (wet) age-related macular degeneration (AMD)

Population group: only adults (18 years old or older)

Brolucizumab is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Brolucizumab is contraindicated in the following cases:

Ocular or periocular infections

at least one of
Eye infection
Infection of skin of eyelid and periocular region

Intraocular inflammation

Uveitis

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: BEOVU Solution for injection
Summary of Product Characteristics (SPC) 2022: BEOVU Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈